1/2: UHCOP-DLDCCC alliance: Cancer drug discovery/development and education

P20应用概述 我们的休斯顿大学药学院（UHCOP）-丹L。邓肯综合癌症中心 （DLDCCC）联盟将为联合药物发现/开发研究计划开发基础设施， 治疗癌症的健康差距和联合癌症研究教育计划（CREP）。这样的组合简直是 基于DLDCCC/Baylor在尖端癌症药物发现技术方面的互补专业知识 医学院（ESTA）和癌症药物的开发在UHCOP。UHCOP是一个组成部分， 休斯敦大学（UH），这是一个服务于服务不足的健康差距人群（IUPS）的机构。 UHCOP教师从IUPS带来了独特的视角，并辅以丰富的 药物发现和开发经验，现有的本科研究计划，以及 在与服务不足的社区合作方面的临床专业知识。DLDCCC，一个NCI指定的综合性 癌症中心，贡献突出的经验和观点，在目前的癌症治疗和临床 试验，尖端药物发现技术和专业知识，癌症研究核心设施，以及现有的 本科生和研究生培训和教育计划，包括癌症患者的健康 差距。UHCOP和USCWA是美国最大的医疗中心德克萨斯医疗中心的成员机构， 世界上UHCOP/DLDCCC联盟将由一个行政核心领导， 在药物发现/开发和癌症生物学研究方面经验丰富的研究人员。内部咨询 委员会（IAC）由经验丰富的资深癌症研究和/或教育专家组成，将指导 联盟，以确保顺利完成拟议的目标。行政核心和临时行政理事会将 担任试点项目共同领导人、CREP和参与的早期研究者的导师， 代表性不足的受训人员。我们选择了两个共同开发和合作的试点项目，从一个 总共六个，以证明药物发现/开发研究联合基础设施的可行性 调查癌症与健康差异这些试点项目有很大的潜力， NIH资助的癌症药物发现/开发计划，并创建最先进的癌症研究培训 机会我们共同开发了一个协同CREP，将鼓励和准备UR学员进入 从事癌症研究。通过研究经验，癌症特定课程和教育推广 为了使工发组织培训人员的努力得到加强，CREP将提供一个长期持续努力的平台， 在癌症研究中的UR受训人员的管道。UHCOP-DLDCCC联盟的最终目标是 通过在药物发现/开发、教育和 新的癌症技术，以满足解决癌症健康差异的未满足需求， 初步数据为成功的后续NCI R型赠款资助。

SUMMARY OF P20 APPLICATION Our University of Houston College of Pharmacy (UHCOP)-Dan L. Duncan Comprehensive Cancer Center (DLDCCC) alliance will develop the infrastructure for a joint drug discovery/development research program to treat cancers with a health disparity and a joint Cancer Research Education Program (CREP). This alliance is built on complementary expertise in cutting-edge cancer drug discovery technologies at DLDCCC/Baylor College of Medicine (BCM) and in development of cancer drugs at UHCOP. The UHCOP is a constituent of the University of Houston (UH), which is an institution serving underserved health disparity populations (ISUPS). UHCOP faculty members bring a unique perspective from an ISUPS, which is complemented by a wealth of pharmaceutical discovery and development experience, existing programs for undergraduate research, and clinical expertise in working with underserved communities. The DLDCCC, an NCI-designated Comprehensive Cancer Center, contributes prominent experience and perspective in current cancer treatments and clinical trials, cutting edge drug discovery technologies and expertise, cancer research core facilities, and existing undergraduate and graduate training and education programs, including those for patients with cancer health disparities. UHCOP and BCM are member institutions of the Texas Medical Center, the largest medical center in the world. The UHCOP/DLDCCC alliance will be led by an Administrative Core, comprised of senior and experienced investigators in drug discovery/development and cancer biology research. The Internal Advisory Committee (IAC), composed of experienced and senior cancer research and/or education experts, will guide the alliance to ensure the successful completion of the proposed goals. The Administrative Core and IAC will serve as mentors to Co-Leaders of pilot projects, the CREP, and participating early-stage investigators and underrepresented (UR) trainees. We have selected two co-developed and collaborative Pilot Projects, from a total of six, to demonstrate the feasibility of the joint infrastructure for drug discovery/development research investigating cancers with health disparities. These pilot projects have strong potential to launch bi-institutional, NIH-funded cancer drug discovery/development programs and create state-of-the-art cancer research training opportunities. We have co-developed a synergistic CREP that will encourage and prepare UR trainees to enter careers in cancer research. Through research experiences, cancer-specific curricula, and education outreach efforts to the UR trainees, the CREP will provide a platform for long-term sustained efforts for enlarging the pipeline of UR trainees in cancer research. The ultimate goal of the UHCOP-DLDCCC alliance will be to support a multiplier effect by developing joint infrastructure in drug discovery/development, education, and novel cancer technologies to target the unmet need of tackling cancer health disparities and generate preliminary data for successful subsequent NCI R-type grant funding.